AP NEWS

Arlington Capital Partners Portfolio Company Molecular Products Group Announces Acquisition of the Henkel SODASORB® Business

December 18, 2018

LOUISVILLE, Colo.--(BUSINESS WIRE)--Dec 18, 2018--Molecular Products Group, (“Molecular Products” or the “Company”), a portfolio company of Arlington Capital Partners (“Arlington Capital”), today announced the acquisition of the SODASORB ® business from Henkel.

The SODASORB ® product range includes carbon dioxide absorbents which have been trusted globally for decades in the healthcare and safety industries. SODASORB ® products help to safely and efficiently remove carbon dioxide from anesthesia systems, saturation diving chambers, diving re-breathers, and industrial safety equipment.

Troy Rhudy, CEO of the Molecular Products Group, said, “We’re delighted to add the SODASORB ® product line to our existing product portfolio. The new capacity will enhance our ability to respond to growing market demands and benefit our entire global customer base, while strengthening our position as the global leader in carbon dioxide absorbent technologies.”

“The acquisition of SODASORB ® further establishes Molecular Products in the strategically important healthcare segment of the business, leveraging the Company’s core chemical technologies and expanding its capabilities,” said Peter Manos, Managing Partner of Arlington Capital Partners.

Malcom Little, a Principal of Arlington, added, “This acquisition demonstrates Molecular Products’ continued focus on highly strategic M&A to expand the Company’s product offerings and enhance its capabilities across all of its segments.”

About Molecular Products

Molecular Products is a Pure Air Technologies company and leading manufacturer of advanced chemistry-based products serving the healthcare, defense and industrial markets. The Company specializes in the manufacture and supply of chemical technologies for the treatment of breathable gases and serves its global customer base out of its two primary manufacturing facilities in Louisville, Colorado, USA and Harlow, Essex, UK. www.molecularproducts.com

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private equity firm that has managed $2.2 billion of committed capital via four investment funds. Arlington is focused on middle market investment opportunities in growth industries, including: aerospace/defense, healthcare, government services and technology, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their Company’s position as leading competitors in their field. www.arlingtoncap.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20181218005552/en/

CONTACT: Louise Santos

lsantos@molprod.com

633 CTC Blvd.

Louisville, CO 80027

(303) 968-2604

Peter Manos & Malcolm Little

Arlington Capital Partners

5425 Wisconsin Avenue, Suite 200

Chevy Chase, MD 20815

(202) 337-7500

KEYWORD: UNITED STATES NORTH AMERICA COLORADO

INDUSTRY KEYWORD: MANUFACTURING CHEMICALS/PLASTICS OTHER MANUFACTURING PROFESSIONAL SERVICES CONSULTING FINANCE COMMUNICATIONS PUBLIC RELATIONS/INVESTOR RELATIONS

SOURCE: Arlington Capital Partners and Molecular Products Group

Copyright Business Wire 2018.

PUB: 12/18/2018 10:16 AM/DISC: 12/18/2018 10:16 AM

http://www.businesswire.com/news/home/20181218005552/en

AP RADIO
Update hourly